Search hospitals > Minnesota > Minneapolis

Minnesota Clinical Study Center

Claim this profile
Minneapolis, Minnesota 55432
Global Leader in Psoriasis
Global Leader in Acne
Conducts research for Plaque Psoriasis
Conducts research for Actinic Keratosis
Conducts research for Alopecia Areata
125 reported clinical trials
1 medical researcher
Photo of Minnesota Clinical Study Center in MinneapolisPhoto of Minnesota Clinical Study Center in Minneapolis

Summary

Minnesota Clinical Study Center is a medical facility located in Minneapolis, Minnesota. This center is recognized for care of Psoriasis, Acne, Plaque Psoriasis, Actinic Keratosis, Alopecia Areata and other specialties. Minnesota Clinical Study Center is involved with conducting 125 clinical trials across 53 conditions. There are 1 research doctors associated with this hospital, such as Steven Kempers.

Top PIs

Clinical Trials running at Minnesota Clinical Study Center

Alopecia
Alopecia Areata
Actinic Keratosis
Seborrheic Keratosis
Fungal Nail Infection
Basal Cell Nevus Syndrome
Basal Cell Carcinoma
Syndrome
Gorlin Syndrome
Male Pattern Baldness
Image of trial facility.

Upadacitinib

for Severe Alopecia Areata

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and face, but hair loss can happen on any part of the body. The purpose of this study is to assess how safe, effective, and tolerable upadacitinib is in adolescent and adult participants with severe AA. Upadacitinib is an approved drug being investigated for the treatment of AA. In Study 1 and Study 2 Period A, participants are placed in 1 of 3 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 5 chance that participants will be assigned to placebo. In Study 1 and Study 2 Period B, participants originally randomized to upadacitinib dose group in Period A will continue their same treatment in Period B. Participants originally randomized to Placebo in Period A will either remain on placebo in Period B, or be randomized in 1 of 2 groups, based off of their Severity of Alopecia Tool (SALT) score. Participants who complete Study 1 or Study 2, can join Study 3 and may be re-randomized to receive 1 of 2 doses of upadacitinib for up to 108 weeks. Around 1500 participants with severe AA will be enrolled in the study at approximately 240 sites worldwide. Participants will receive oral tablets of either upadacitinib or placebo once daily for up to 160 weeks with the potential of being re-randomized into a different treatment group at Weeks 24 and 52. Participants will be followed up for up to 30 days after last study drug dose. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Recruiting1 award Phase 34 criteria
Image of trial facility.

PP405

for Male Pattern Baldness

The study is designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK following 28 days of administration.
Recruiting0 awards Phase 22 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Minnesota Clinical Study Center?
Minnesota Clinical Study Center is a medical facility located in Minneapolis, Minnesota. This center is recognized for care of Psoriasis, Acne, Plaque Psoriasis, Actinic Keratosis, Alopecia Areata and other specialties. Minnesota Clinical Study Center is involved with conducting 125 clinical trials across 53 conditions. There are 1 research doctors associated with this hospital, such as Steven Kempers.